ResearcherGerman Cancer Research CenterActive in the last 2 years
Christine E. Engeland
Matched on ORCID iD 0000-0001-6032-8786; OpenAlex author ID A5050832985. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 18
2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper
Papers 5
- Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures. Last author DOI 10.1016/j.ebiom.2024.105219↗
- Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model. Last author DOI 10.3389/fimmu.2022.1096162↗
- MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer. Co-author DOI 10.1016/j.omto.2021.04.015↗
- Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcino… Co-author DOI 10.1158/1078-0432.ccr-21-1020↗
- A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pan… Co-author DOI 10.1186/s12885-017-3604-y↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Guy Ungerechts · 5 shared papers, 2017–2024 · strength 0.56
- Paper Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures. DOI 10.1016/j.ebiom.2024.105219↗
- Paper Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity i… DOI 10.3389/fimmu.2022.1096162↗
- Paper MicroRNA-sensitive oncolytic measles virus for chemovirotherapy of pancreatic cancer. DOI 10.1016/j.omto.2021.04.015↗
- Claudia R. Ball · 2 shared papers, 2022–2024 · strength 0.28
- Theresa E. Schäfer · 2 shared papers, 2022–2024 · strength 0.28
- Albrecht Stenzinger · 2 shared papers, 2017–2022 · strength 0.19
- Paper Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity i… DOI 10.3389/fimmu.2022.1096162↗
- Paper A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in … DOI 10.1186/s12885-017-3604-y↗
- Niels Halama · 2 shared papers, 2017–2021 · strength 0.15
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Paper A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in … DOI 10.1186/s12885-017-3604-y↗
- Assia L. Angelova · 2 shared papers, 2017–2021 · strength 0.15
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Paper A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in … DOI 10.1186/s12885-017-3604-y↗
- Christoph Springfeld · 2 shared papers, 2017–2021 · strength 0.15
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Paper A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in … DOI 10.1186/s12885-017-3604-y↗
- Jacek Hajda · 2 shared papers, 2017–2021 · strength 0.15
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Paper A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in … DOI 10.1186/s12885-017-3604-y↗
- Florian Gebauer · 1 shared paper, 2024 · strength 0.15
- Rob C. Hoeben · 1 shared paper, 2024 · strength 0.15
- Lukas J.A.C. Hawinkels · 1 shared paper, 2024 · strength 0.15
- Selas T. F. Bots · 1 shared paper, 2024 · strength 0.15
- Vera Kemp · 1 shared paper, 2024 · strength 0.15
- Rūta Veinalde · 1 shared paper, 2022 · strength 0.14
- Sascha Bossow · 1 shared paper, 2021 · strength 0.12
- Hans Martin Singh · 1 shared paper, 2021 · strength 0.12
- Nicolas Hohmann · 1 shared paper, 2021 · strength 0.10
- Matthias M. Gaida · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.